AVUV vs IBB
Avantis US Small Cap Value ETF vs iShares Biotechnology ETF
- • AVUV has the lower expense ratio at 0.25% vs 0.44% for IBB.
- • AVUV pays a higher dividend yield (1.25%).
Side-by-side metrics
| Metric | AVUV | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.25% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $29.06B | $9.09B |
YTD return | 20.76% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 0.69 |
P/E ratio | 13.54 | 24.89 |
Last price | $123.22 | $197.34 |
Inception | — | — |
Issuer | Avantis | iShares |
AVUV top holdings
| VSAT | Viasat Inc | 1.39% |
| MATX | Matson Inc | 1.02% |
| LNTH | Lantheus Holdings Inc | 0.86% |
| IRDM | Iridium Communications Inc | 0.78% |
| AVT | Avnet Inc | 0.78% |
| M | Macy's Inc | 0.76% |
| LEA | Lear Corp | 0.75% |
| GATX | GATX Corp | 0.74% |
| AROC | Archrock Inc | 0.73% |
| CBT | Cabot Corp | 0.73% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About AVUV
AVUV (Avantis US Small Cap Value ETF) is US small-cap value with profitability screen. Managed by Avantis, the fund carries $29.1B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.25%. Its largest holding is Viasat Inc (VSAT), which represents 1.4% of the portfolio. Real Estate is the fund's largest sector exposure at 0.7%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.